Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. - sprookjes - yvandenbroek - TriplyDB

Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

http://www.wikidata.org/entity/Q35635562

about

Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments Hallmarks of glycosylation in cancer Nuclear transport of galectin-3 and its therapeutic implications Galectins in epithelial functions Cancer Therapy Due to Apoptosis: Galectin-9.Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins Correlation between Polymorphism of TRAIL Gene and Condition of Intervertebral Disc Degeneration.Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.Galectin-3 as a Potential Target to Prevent Cancer Metastasis.A putative molecular network associated with colon cancer metastasis constructed from microarray data.Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.LGALS3 and AXIN1 gene variants playing role in the Wnt/ β-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer Glycobiology of cell death: when glycans and lectins govern cell fate.Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics.Inhibition of eIF2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells.N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.Resistance to TRAIL and how to surmount it.Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game.Protein trafficking in colorectal carcinogenesis-targeting and bypassing resistance to currently applied treatments.Surviving apoptosis: life-death signaling in single cells.Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.A genome-wide CRISPR screen reconciles the role of N-linked glycosylation in galectin-3 transport to the cell surface.An RNA interference screen identifies new avenues for nephroprotection.Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra.TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame.TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death.Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.Precision engineering of targeted nanocarriers.Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis.

P2860

Q26744513-4F95D3B3-5CAD-4C22-98A9-ACFF33EB28C8 Q26752363-9269DAB8-C3DD-4401-88CB-96EB9F2F35B8 Q26824889-F2238149-8FB8-4FC3-BC22-6B71763DB512 Q27000800-AAFA06CB-3533-4106-99B6-B7E22C47A022 Q30397015-DA456588-9640-428B-86C0-B31F3D25BC35 Q30398758-116398EF-F8ED-4AA7-851D-A6FD25835B43 Q30544925-998E4EE2-C1F8-4287-B7B0-015D4C1446F2 Q34831682-8875B953-FE83-41CA-BAA0-35C45D56B7F8 Q35939523-17F636EC-8050-4808-83DF-BB58EFAACE70 Q35955331-FB5D8A53-9F6A-4A12-ABEA-B7DF2DFC12C4 Q36326176-D376949E-3A38-4D93-8D30-4FCD65C18CF1 Q36409632-F8BD8EA0-8390-4E1A-BDA0-5C73FC08352C Q36440083-47ED8DB0-785E-4D82-B4D9-1AE0A02F33F8 Q36857748-8A1FC2D8-4ECA-40D0-9F42-A1F5EEB09CD8 Q36994801-48277188-322B-4C08-A1ED-F7F0E6D1F908 Q37003894-38AE017A-9092-4CD1-9653-A6B29D4FAEEE Q37299331-EF14B85F-96C7-4C26-89BF-3A36F7D0CBCA Q37412506-E7FBACF6-86B0-4AE3-AD22-394494F4118E Q37620650-DA3A7D37-5C7B-4313-AFEE-60DE3897679E Q37691437-41925C7E-AE5B-4270-A4F2-304BC95FFBC7 Q37992546-484A1186-5588-47AB-99F1-BC54276179B4 Q38035209-1538245E-6080-4F8A-96F6-18BE926CB605 Q38415868-B47839B7-F543-43F2-8ED0-10C840C200EB Q38446898-C7BEF4D2-828A-4AA9-919D-B69997EB2E92 Q38575137-7A4364C6-5F69-4921-BAE0-E126B747FD52 Q38642366-9C211B21-9C8F-42F1-B470-98CF39779C66 Q38819738-5DA40CCE-4489-401D-B9BB-51AEF1C12C38 Q38902765-3B5EDB09-B6C7-4641-BE4F-16BEBBBB4453 Q39305649-7FCD4EB7-D898-4AE3-BE2F-A7662B99781F Q41123139-19579CF8-0F57-4CF5-BF86-205D72BD18CA Q41557413-3FD2E982-5F50-4159-8D7B-EDBDD8E53A69 Q42317467-278E3790-CEA8-4B23-B52C-5A675B6539CE Q46209871-B2EA889D-1DE1-4C24-BDD5-F021A9E6F34B Q47292379-687B5A6F-C53C-402B-82A0-CD1504C9F806 Q50049633-1E1E2813-D6B6-462B-BEF3-78F2E821B7C5 Q52369544-788C03A3-C66B-48E7-81D3-F7DE797358D5 Q55156410-1768581C-5A0F-4550-AF90-A61B5B5CD195

P2860

Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

http://www.wikidata.org/entity/Q35635562

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@ast

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@en

type

label

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@ast

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@en

prefLabel

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@ast

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@en

P1433

Q35635562-2F3EBDF2-43DB-4561-B05B-F5D68F00F87C

P1476

Q35635562-688FA942-4A6C-4737-A673-69F8A7418FE9

P2093

Q35635562-3CC55F82-29F9-42A3-B925-1B004AC25239

Q35635562-3CF29FBE-A098-4A12-9D19-6D6DD7F0A58C

Q35635562-69588795-8B83-4312-92CF-8F5B647E496A

Q35635562-8CF622BE-0D21-41AB-B2ED-7CEB489DE200

Q35635562-B970C219-E62D-4E1E-A529-6080B082495E

Q35635562-E3455F0B-D9DC-437B-AB77-A48F0CECAA5A

Q35635562-F245EC99-EF82-4546-893D-BB15F366861C

P2860

Q35635562-0AA785F2-D9E8-47C6-9049-319BB81572F0

Q35635562-194B1E31-4BA8-4270-AA3A-95C45E607D8F

Q35635562-1C8CF658-1D9B-4D19-8365-1A10C20DD12A

Q35635562-1CDF3CBF-8E59-478F-B312-FF8A2F5FC479

Q35635562-20DA68E2-8A97-46A8-AD6D-D4DF60C58A70

Q35635562-21894B79-A2C3-475F-823D-F9AD194D6196

Q35635562-272854CE-8C61-42C4-A61D-E17FC19FD107

Q35635562-2B9E8598-1A13-4594-9BD9-BF04AE1AE8D2

Q35635562-2BF9236D-6D17-4DE9-ABA0-753E37CCC768

Q35635562-2CDC3305-AE20-40D2-8405-03763DC0199A

P2888

Q35635562-7ECE9BBB-E08D-40AB-92B8-7D696D8A3C2C

P304

Q35635562-5182438D-408C-49AB-BF73-895158D5C71C

P31

Q35635562-019571F8-0AB5-4AF2-80C9-DF4CD84D881D

P356

Q35635562-01C20095-7CEB-4B15-BAC2-E187DB410DCC

P433

Q35635562-6B1049AB-DD19-471C-8128-BA9C3FFECC1D

P478

Q35635562-46A67515-1043-46F6-BBF9-F5A86485612B

P577

Q35635562-4076F927-FF68-4D00-9A32-CD1D64EA069C

P5875

Q35635562-0B3479C1-64F0-48FC-8E65-59F356D3A5D8

P6179

Q35635562-49D32DB7-FC0A-4FEF-98C7-139109CC5436

P698

Q35635562-113E62C8-6823-4DFB-97EB-A3516BE4ABD8

P921

Q35635562-E98B8F83-5311-4166-8ADB-2D3B578C3EAF

P932

Q35635562-415953D7-E575-4AF7-B1B1-591D291670CD

P356

P1433

Cell Death & Differentiation

P1476

Cell-surface galectin-3 confer ...... ic colon adenocarcinoma cells.

@en

P2093

J Burks

http://www.w3.org/2001/XMLSchema#string

J C Byrd

http://www.w3.org/2001/XMLSchema#string

K Ramirez

http://www.w3.org/2001/XMLSchema#string

M Hafley

http://www.w3.org/2001/XMLSchema#string

N Mazurek

http://www.w3.org/2001/XMLSchema#string

R S Bresalier

http://www.w3.org/2001/XMLSchema#string

Y Sun

http://www.w3.org/2001/XMLSchema#string

P2860

The role of receptor internalization in CD95 signaling.

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts

Death and anti-death: tumour resistance to apoptosis

Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death

Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling.

A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Glioma-associated cancer-initiating cells induce immunosuppression.

P2888

P304

523-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CDD.2011.123

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51664825

http://www.w3.org/2001/XMLSchema#string

P6179

1051747931

http://www.w3.org/2001/XMLSchema#string

P698

21941373

http://www.w3.org/2001/XMLSchema#string

P921

P932

3246527

http://www.w3.org/2001/XMLSchema#string